Can tyrosine‑kinase inhibitors used for non‑small‑cell lung cancer cause pneumonitis or other pulmonary toxicities?

Can TKIs in NSCLC Induce Pneumonitis or Other Lung Toxicities?

Yes, tyrosine kinase inhibitors used for non-small-cell lung cancer can cause pneumonitis and other pulmonary toxicities, with pneumonitis being one of the most serious and potentially fatal complications requiring immediate recognition and management. 1, 2

Incidence and Epidemiology

EGFR-TKI Associated Pneumonitis

• Osimertinib-associated pneumonitis occurs in approximately 3% of treated patients (all grades) and in approximately 0.5% as grade 3-4 toxicity, with documented fatal events 2
• Japanese patients experience markedly higher incidence of EGFR-inhibitor pneumonitis (4.77%) compared with non-Japanese cohorts (0.55%), making ethnicity an independent risk factor 2, 3
• Meta-analysis data demonstrate that erlotinib, gefitinib, and afatinib are associated with a significantly increased risk of high-grade interstitial lung disease (relative risk 4.18,95% CI: 2.49-7.01; p < 0.00001) 4

ALK-TKI Associated Pneumonitis

• Overall incidence of ALK-inhibitor pneumonitis ranges from 1.14% to 6.25%, with increased rates in Japanese populations 2, 5
• Brigatinib carries the highest risk among ALK inhibitors, with pneumonitis occurring in 7% of exposed patients (all grades) and 3.06% high-grade events 5, 3
• Crizotinib-associated pneumonitis occurs in 1.8% of patients, while ceritinib (1.1%), alectinib (2.6%), and lorlatinib (1.8%) have lower but still clinically significant rates 5, 6
• Mortality rate from ALK-TKI pneumonitis is approximately 9%, with 65% of cases being grade 3 or 4 events 5

Combination Therapy Risks

• Combining TKIs with immune checkpoint inhibitors dramatically increases pneumonitis risk: durvalumab plus osimertinib resulted in 38% pneumonitis incidence in the TATTON trial cohort 1
• Sequential therapy also poses risk: relevant toxicities have been reported when TKIs are given after initial immunotherapy, possibly due to the long half-life of ICI compounds 1
• ICIs as monotherapy are not recommended before other standard therapeutic options in EGFR-mutant lung cancer due to limited efficacy and increased risk of toxicity with subsequent TKI treatment 1

Clinical Presentation and Timing

Onset Patterns

• Median time to onset of drug-related pneumonitis is 34 weeks (range 1.5-127 weeks), though it can occur as early as 1.5 weeks after therapy initiation 2
• Earlier onset in NSCLC patients compared to other malignancies: median 2.1 months (range 0.2-27.4 months) 1
• Acute presentations can occur within 3 weeks of starting therapy, as documented with lorlatinib 6

Radiographic Patterns

• Five main CT patterns can be observed: organizing pneumonia (OP), diffuse alveolar damage (DAD), hypersensitivity pneumonitis (HP), nonspecific interstitial pneumonia (NSIP), or pulmonary eosinophilia 2
• The DAD pattern on CT is associated with poor prognosis and mandates immediate discontinuation of the offending targeted agent together with high-dose corticosteroids 2
• Organizing pneumonia is the most common pattern with certain agents, particularly mTOR inhibitors 2

Clinical Symptoms

• Patients may present with new or worsening shortness of breath, cough, wheezing, chest pain, reduced exercise tolerance, fatigue with activities of daily living, and new or increasing requirement for supplementary oxygen 1
• Clinical presentations may be asymptomatic (grade 1, radiologic only) or progress to severe respiratory failure 2

Other Pulmonary Toxicities Beyond Pneumonitis

Additional Lung-Related Adverse Events

• Pleural effusions, pulmonary sarcoidosis, and sarcoid-like granulomatous reactions have been reported following both CTLA-4 and PD-1/PD-L1-targeted therapies 1
• Epistaxis occurs in 17% of EGFR-TKI treated patients (afatinib data) 7
• Rhinorrhea affects 11% of patients 7

Common Non-Pulmonary Toxicities

The most common adverse events with EGFR-TKIs are gastrointestinal (diarrhea, stomatitis/mucositis) and cutaneous (rash, dry skin, paronychia), which can negatively impact quality of life and lead to dose modifications or discontinuation 1

Diagnostic Approach

Immediate Assessment

• Obtain urgent chest CT (not plain radiograph) when pneumonitis is suspected; plain radiography is insufficient for accurate characterization 2
• Bronchoscopy with bronchoalveolar lavage (BAL) is recommended to exclude infectious etiologies (including Pneumocystis, mycobacteria, viruses), alveolar hemorrhage, or lymphangitic spread 2
• BAL may reveal eosinophilia suggestive of drug reaction, though this finding is often nonspecific 2

Risk Stratification

• Japanese ethnicity is an independent risk factor requiring heightened vigilance 2, 3
• Prior chemotherapy increases risk: ALK TKI treatment after chemotherapy is associated with higher incidence of all-grade (7.73% vs. 2.26%) and high-grade (3.64% vs. 1.26%) pneumonitis compared to first-line ALK TKI treatment 3
• Preexisting lung disease (COPD, pulmonary fibrosis) makes diagnosis particularly challenging and failure to recognize pneumonitis in a timely manner could lead to poor outcomes 1, 8

Management Algorithm

Grade 1 (Asymptomatic, Radiologic Only)

• Continue targeted therapy with close monitoring 2
• Monitor symptoms every 2-3 days 1
• Repeat chest CT prior to next scheduled dose 1

Grade ≥2 Pneumonitis

• Discontinue the targeted therapy immediately 2
• Initiate systemic corticosteroids while continuing diagnostic evaluation 2
• Patients typically require hospitalization for grade 3 or higher 1

DAD Pattern on Imaging

• Immediate discontinuation of targeted therapy is mandatory due to high mortality risk 2
• Initiate high-dose corticosteroids 2
• Do not continue or rechallenge with the offending agent 2

Treatment Discontinuation

• Drug withdrawal is the mainstay of treatment for pneumonitis of all grades 1
• For grade 1 pneumonitis, rechallenge following resolution of infiltrates and close follow-up is reasonable 1
• 25% of patients with ALK-TKI pneumonitis permanently discontinued treatment due to lung toxicity 5

Critical Pitfalls to Avoid

• Do not rely on chest radiography alone: high-resolution CT is mandatory for accurate characterization of pneumonitis 2
• Do not dismiss new pulmonary opacities as simple pneumonia without evaluating for drug-related pneumonitis, which can be fatal if the offending agent is continued 2
• Do not continue targeted therapy when a DAD pattern is identified on CT, given its association with high mortality 2
• Never start immunotherapy before confirming EGFR/ALK status, as EGFR-mutant disease shows markedly reduced benefit and higher toxicity when treated with ICIs, and subsequent TKI therapy carries increased pneumonitis risk 1, 9
• Avoid combining checkpoint ICIs with TKIs due to dramatically increased pneumonitis rates (up to 38% with durvalumab plus osimertinib) 1

Prognostic Considerations

• Pneumonitis is one of the most common causes of ICI-related death, making early recognition critical 1
• Poor prognoses are expected when there is a short interval from initiation of targeted therapy to onset of ILD, acute interstitial pneumonia pattern, and preexisting pulmonary fibrosis 8
• Paradoxically, patients who develop transient, asymptomatic pulmonary opacities while on osimertinib have been observed to experience longer progression-free and overall survival, suggesting a possible link between this phenomenon and treatment benefit 2